SAN FRANCISCO, Oct. 3, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it gained FDA market authorization for its Common Hereditary Cancers Panel. This ...

Allelica and Invitae (NVTA) aim to decrease the gap in polygenic risk score (PRS) performance in individuals from diverse genetic ancestries, ensuring that the life-saving integration of genomic ...

Microsatellite Peak Shifts in Polymerase Chain Reaction-Based Fragment Length Data Correlate With Microsatellite Instability Degree and Vary With Mismatch Repair Gene Defects and Tumor Size This was a ...

A retrospective study was performed to analyze the results of clinical germline genetic testing (March 2020-January 2023) among a cohort of consecutive Emirati patients at risk for hereditary breast ...